FLT3 and acute myeloid leukemia: Several small-molecule FLT3 inhibitors have been evaluated clinically, and gilteritinib was the first FDA-approved FLT3 inhibitor to have been launched in the US for the treatment of relapsed/refractory FLT3-mutant AML.